

PRODUCT INFORMATION

SARS-CoV-2 Spike Glycoprotein S1 Subunit Rabbit Monoclonal Antibody (Clone 007)

Item No. 31995

Overview and Properties

Contents:	This vial contains 50 or 100 µl of protein A-affinity purified recombinant monoclonal antibody.
Synonyms:	SARS-CoV Surface Glycoprotein S1 Subunit, Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein S1 Subunit
Immunogen:	Recombinant SARS-CoV spike glycoprotein S1 subunit (C-terminal His-tagged)
Cross Reactivity:	See page 2
Species Reactivity:	See page 2
Form:	Liquid
Storage:	-80°C (as supplied)
Stability:	≥1 year
Storage Buffer:	0.2 µm filtered solution in PBS
Clone:	007
Host:	Rabbit
Isotype:	IgG
Application:	ELISA; the recommended starting dilution is 1:5,000-1:10,000. Other applications were not tested, therefore optimal working concentration/dilution should be determined empirically.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/04/2023

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Reactivity

Cross Reactivity: (+) SARS-CoV spike glycoprotein RBD,
SARS-CoV-2 spike glycoprotein RBD,
SARS-CoV-2 Omicron (XBB) spike glycoprotein RBD,
SARS-CoV-2 Omicron (BQ.1.1) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Omicron (BQ.1.1) spike glycoprotein RBD,
SARS-CoV-2 Omicron (BF.7) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Omicron (BA.4.6/BF.7) spike glycoprotein RBD,
SARS-CoV-2 (BA.4.6) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 (BA.2.75) spike glycoprotein RBD,
SARS-CoV-2 (BA.2.75) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Omicron (BA.2.75.2) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Omicron (BA.2.75.2) spike glycoprotein RBD,
SARS-CoV-2 (BA.2.3.20) spike glycoprotein RBD,
SARS-CoV-2 Omicron (BA.1.1) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Omicron (BA.1.1) spike glycoprotein RBD,
SARS-CoV-2 Omicron (BA.1.1.529) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Omicron (BA.1.1.529) spike glycoprotein RBD,
SARS-CoV-2 Omicron (BA.2) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Omicron (BA.2) spike glycoprotein RBD,
SARS-CoV-2 Omicron (BA.2.12.1) spike glycoprotein RBD,
SARS-CoV-2 Omicron (BA.4) spike glycoprotein RBD,
SARS-CoV-2 XD (BA.1 x AY.4) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Delta (B.1.617.2) spike glycoprotein S1+S2 trimer,
SARS-CoV-2 Delta (B.1.617.2) spike glycoprotein S1+S2,
SARS-CoV-2 Delta (B.1.617.2) spike glycoprotein RBD,
SARS-CoV-2 Omicron (BA.5) spike glycoprotein RBD;

(-) SARS-CoV-2 Omicron (BA.2) spike glycoprotein S1 subunit NTD,
SARS-CoV-2 Delta (B.1.617.2) spike glycoprotein S1 subunit NTD,
HCoV-OC43 spike glycoprotein S1+S2 ECD

Species Reactivity: (+) SARS-CoV,
SARS-CoV-2,
SARS-CoV-2 Omicron (B.1.1.529),
SARS-CoV-2 Omicron (BA.2),
SARS-CoV-2 Delta (B.1.617.2);

(-) MERS-Cov,
HCoV-HKU1 (isolate N1),
HCoV-HKU1 (isolate N5),
HCoV-NL63,
HCoV-229E

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Severe acute respiratory syndrome coronavirus (SARS-CoV) spike glycoprotein, also known as the surface glycoprotein, is encoded by the *S* gene in SARS-CoV RNA.¹ SARS-CoV is a member of the *Betacoronavirus* genus of viruses and has an approximately 79% sequence identity with SARS-CoV-2, the causative agent of COVID-19.^{2,3} The spike protein of SARS-CoV and the related viruses SARS-CoV-2 and Middle East respiratory syndrome coronavirus (MERS-CoV) is a transmembrane glycoprotein that assembles into homotrimers on the virus surface and is comprised of an N-terminal S1 subunit, which contains the receptor binding domain (RBD), and a C-terminal S2 subunit, which facilitates fusion between viral and host cell membranes.⁴⁻⁶ The 193-amino acid RBD of the SARS-CoV spike protein is a target for neutralizing antibodies.^{5,7} The SARS-CoV RBD, which spans amino acid residues 318 to 510, is 73% identical to that of SARS-CoV-2 and can bind to human angiotensin-converting enzyme 2 (ACE2), which is the host cell surface receptor for both SARS-CoV and SARS-CoV-2.⁴⁻⁷ SARS-CoV is the causative agent of SARS, a primarily respiratory illness characterized by fever, cough, shortness of breath, and an approximately 10% fatality rate.³ Cayman's SARS-CoV Spike Glycoprotein S1 Subunit Rabbit Monoclonal Antibody (Clone 007) can be used for ELISA. The antibody recognizes the S1 subunit from SARS-CoV and SARS-CoV-2.

References

1. Kandeel, M., Ibrahim, A., Fayez, M., *et al.* From SARS and MERS CoVs to SARS-CoV-2: Moving toward more biased codon usage in viral structural and nonstructural genes. *J. Med. Virol.* **92(6)**, 660-666 (2020).
2. Lu, R., Zhao, X., Li, J., *et al.* Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. *Lancet* **395(10224)**, 565-574 (2020).
3. Meo, S.A., Alhowikan, A.M., Al-Khlaiwi, T., *et al.* Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. *Eur. Rev. Med. Pharmacol. Sci.* **24(4)**, 2012-2019 (2020).
4. Liu, Z., Xiao, X., Wei, X., *et al.* Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. *J. Med. Virol.* **92(6)**, 595-601 (2020).
5. He, Y., Zhou, Y., Liu, S., *et al.* Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine. *Biochem. Biophys. Res. Commun.* **324(2)**, 773-781 (2004).
6. Walls, A.C., Park, Y.-J., Tortorici, M.A., *et al.* Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* **181(2)**, 281-292 (2020).
7. Tian, X., Li, C., Huang, A., *et al.* Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. *Emerg. Microbes Infect.* **9(1)**, 382-385 (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM